by JDRF Bay Area
03.10.2011
Research & Technology
This trial is another step forward for JDRF’s research focus on Immune Therapies aim at stopping or slowing type 1 diabetes progression in people who are newly diagnosed.
Read the full article →
by JDRF Bay Area
07.21.2010
Research & Technology
ShareParis, France – July 1, 2010 – Sanofi-aventis (EURONEXT: SAN and NYSE: SNY ) and the Juvenile Diabetes Research Foundation (JDRF) announced today a unique partnership to develop therapeutic treatments for people with type 1 diabetes at different stages of the disease – both those living with the disease and the newly diagnosed – as [...]
Read the full article →
